Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 10/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | PRKDC | P78527 | 2/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5445887 | 0.85 | NR1H2 (0.53) | IGF1RMAOBPRKDCBACE1NR1H2 | |
| SCHEMBL5442245 | 0.81 | MAOB (0.51) | IGF1RMAOBBACE1NR1H2 | |
| SCHEMBL5436610 | 0.80 | MAP4K4 (0.53) | — | |
| SCHEMBL3792137 | 0.79 | MAOB (0.61) | IGF1RMAOBPRKDCPIK3CDPIK3CA | |
| SCHEMBL5443961 | 0.79 | IKBKB (0.51) | IGF1RMAOB | |
| SCHEMBL17731204 | 0.77 | PIK3CD (0.57) | IGF1RMAOBPRKDCPIK3CDPIK3CA | |
| SCHEMBL14115599 | 0.77 | PIK3CG (0.52) | IGF1RMAOBPRKDCPIK3CDPIK3CA | |
| SCHEMBL379281 | 0.75 | MAOB (0.67) | MAOB | |
| SCHEMBL1718139 | 0.75 | AURKB (0.62) | IGF1R | |
| SCHEMBL5442223 | 0.75 | PIK3CD (0.52) | PIK3CDPIK3CGTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| EP-1689718-A1 | 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 ACTIVITY | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049577-A1 | 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | ALK, NPR3, CBR3 | IGF1R 588/4885MAOB 2506/4885PRKDC 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.